THE WHAT? Nine members of the US Congress have written to Revlon Group Holdings CEO Michelle Peluso seeking answers following an FDA warning over testing and quality-control deficiencies at the company’s Oxford, North Carolina manufacturing facility.
THE DETAILS The congressional letter, led by Representative Yvette D. Clarke, follows a June FDA warning letter that identified significant Current Good Manufacturing Practice violations involving Revlon’s OTC drug manufacturing. The FDA said Revlon had not demonstrated adequate testing of incoming talc for asbestos and identified deficiencies in its specifications and quality controls, including microbiological standards for yeast and mould. The agency requested testing of affected talc or finished products, a risk assessment and a remediation plan. The lawmakers raised particular concerns about potential exposure among Black women and girls, citing their significant participation in the US beauty and personal care market.
THE WHY? The congressional intervention increases regulatory and political scrutiny of Revlon’s manufacturing and ingredient-testing controls, highlighting the importance of supplier verification, contaminant testing and robust quality systems for cosmetics companies manufacturing OTC beauty and personal care products in the US.
Source: clarke.house
